Known targets — ChEMBL curated mechanism
ACHEBDKRB2CHRM1CHRM2CHRM3CHRNA1CHRNB1CHRNDCHRNECHRNGGUCY1A1GUCY1A2GUCY1B1GUCY1B2NAMPTPTAFRSLC10A2SLC6A2SLC6A3TACR1dacAdacBdacCftsImrcAmrcBmrdA
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 1/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.35 |
| ▸ | HTR2A | P28223 | 1/20 | 0.31 |
| ▸ | ESR1 | P03372 | 1/20 | 0.30 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL1582634 | 0.86 | TDP1 (0.41) | CYP3A4TDP1ESR1ESR2 | |
| SCHEMBL301134 | 0.86 | TDP1 (0.45) | CYP3A4TDP1ESR1ESR2 | |
| Acetic Acid SCHEMBL1869251 | 0.85 | CYP3A4 (0.32) | CYP3A4TDP1ESR1ESR2 | |
| Bromide SCHEMBL28443974 | 0.84 | TDP1 (0.43) | CYP3A4TDP1ESR1ESR2 | |
| Iodide SCHEMBL1478204 | 0.84 | TDP1 (0.43) | CYP3A4TDP1ESR1ESR2 | |
| SCHEMBL4326950 | 0.84 | TDP1 (0.43) | CYP3A4TDP1HTR2AESR1ESR2 | |
| Bromide SCHEMBL29193727 | 0.84 | TDP1 (0.43) | CYP3A4TDP1ESR1ESR2 | |
| Bromide SCHEMBL1582391 | 0.81 | TDP1 (0.41) | CYP3A4TDP1ESR1ESR2 | |
| Ethane SCHEMBL5591026 | 0.81 | CYP3A4 (0.45) | CYP3A4TDP1ESR1ESR2 | |
| Hydrochloric Acid SCHEMBL344266 | 0.80 | LMNA (0.31) | CYP3A4TDP1HTR2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1690847-B1 | pi-conjugated compound having cardo structure, process for the preparation thereof and use thereof | TOSOH CORP (JP) | 2016-06-22 | — | — | EP | disclosed |
| US-20060186797-A1 | Pi-conjugated compound having cardo structure, process for preparing same and use of same | TOSOH CORPORATION (JP) | 2006-08-24 | — | — | US | disclosed |
| EP-1690847-A1 | pi-Conjugated compound having cardo structure, process for the preparation thereof and use thereof | Tosoh Corporation (JP) | 2006-08-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060186797-A1 | Pi-conjugated compound having cardo structure, process for preparing same and use of same | ARL1, TERB1, LEO1 | CYP3A4 507/4885TDP1 2751/4885HTR2A 1324/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.